Peer-influenced content. Sources you trust. No registration required. This is HCN.
Cancer Therapy Advisor
The median post-rebate spending per beneficiary was higher for the low-added-benefit drugs ($70,524) than for the high-added-benefit drugs ($61,277).
Clinical Pharmacology April 29th 2025
Verywell Health
A Lilly spokesperson told Verywell that about 10% of people who start taking Zepbound for the first time enroll in the self-pay program. This includes people who previously used compounded tirzepatide.
Clinical Pharmacology April 8th 2025
Oncology News Central (ONC)
A section of the new report titled ‘Collapse of Cancer Care’ details how staffing shortages, inadequate resources, and poor management at HCA Mission Hospital led to a severe decline in oncology services.
Hematology/Oncology March 31st 2025
Infectious Disease Advisor
“Congressional action is required to prevent the severe limitations on telehealth that existed before the COVID-19 pandemic from being restored,” said American Medical Association president Bruce A. Scott, MD.
All Specialties March 5th 2025
Psychiatry Advisor
Reclassifying marijuana from Schedule I to a lower schedule would significantly ease the regulatory burden on researchers.
Neurology February 20th 2025
MedCentral
With more potent forms of opioids on the street, overdoses from illicit drugs are at an all-time high and withdrawal from them is often more severe.
Pain Medicine February 20th 2025